Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding

DiaMedica Therapeutics (DMAC) Shares Issued (2018 - 2026)

DiaMedica Therapeutics filings provide 7 years of Shares Issued readings, the most recent being $420000.0 for Q1 2026.

Quarterly Shares Issued rose 346.81% to $420000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Mar 2026, up 278.86% year-over-year, with the annual reading at $1.0 million for FY2025, 290.62% up from the prior year.
Shares Issued hit $420000.0 in Q1 2026 for DiaMedica Therapeutics, up from $278000.0 in the prior quarter.
Across five years, Shares Issued topped out at $11.7 million in Q2 2024 and bottomed at -$36.8 million in Q4 2023.
Average Shares Issued over 4 years is -$3.5 million, with a median of $108500.0 recorded in 2024.
The largest annual shift saw Shares Issued crashed 290250.0% in 2024 before it skyrocketed 346.81% in 2026.
DiaMedica Therapeutics' Shares Issued stood at -$36.8 million in 2023, then surged by 100.33% to $123000.0 in 2024, then surged by 126.02% to $278000.0 in 2025, then surged by 51.08% to $420000.0 in 2026.
Per Business Quant, the three most recent readings for DMAC's Shares Issued are $420000.0 (Q1 2026), $278000.0 (Q4 2025), and $722000.0 (Q3 2025).